Company Encyclopedia
View More
name
JINGHUA PHARM
002349.SZ
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd.
3.159 T
002349.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking47/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.58%B
    • Profit Margin15.51%A
    • Gross Margin51.87%B
  • Growth ScoreC
    • Revenue YoY0.83%C
    • Net Profit YoY3.79%C
    • Total Assets YoY8.12%B
    • Net Assets YoY6.66%B
  • Cash ScoreC
    • Cash Flow Margin644.69%C
    • OCF YoY0.83%C
  • Operating ScoreC
    • Turnover0.43C
  • Debt ScoreA
    • Gearing Ratio11.28%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    JINGHUA PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 176 million yuan, a year-on-year increase of 7.39%

    According to the Zhitong Finance APP, JINGHUA PHARM released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.092 billion yuan, a year-on-year increase of 4.51%. The net profit attributable to shareholders of the listed company was 176 million yuan, a year-on-year increase of 7.39%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 170 million yuan, a year-on-year increase of 9.17%

    Zhitong·
    SZ
    002349
    -1.36%
    Zhitong·
    SZ
    002349
    -1.36%

    JINGHUA PHARM: The company's medical sodium alginate wound dressing has obtained a medical device registration certificate

    On September 18th, JINGHUA PHARM announced that its medical sodium alginate wound dressing has obtained the "Medical Device Registration Certificate of the People's Republic of China" issued by the Jiangsu Provincial Drug Administration. This product is suitable for the care of superficial wounds and surrounding skin

    Zhitong·
    SZ
    002349
    -1.36%
    Zhitong·
    SZ
    002349
    -1.36%

    JINGHUA PHARM's subsidiary LuHuaSenXuan leads the formulation of an industry standard approved by the National Standardization Administration

    According to the Zhitong Finance APP, JINGHUA PHARM announced that the industry standard for "1,3-Dioxolane" led by its subsidiary Shandong Luhuasenxuan New Materials Co., Ltd. (referred to as "Luhuasenxuan") has passed the review by the National Standardization Administration and has been announced by the Ministry of Industry and Information Technology. This standard will officially take effect on March 1, 2026

    Zhitong·
    SZ
    002349
    -1.36%
    Zhitong·
    SZ
    002349
    -1.36%

    JINGHUA PHARM: Net profit of 131 million yuan in the first half of 2025, a year-on-year decrease of 3.54%

    JINGHUA PHARM announced that in the first half of 2025, operating revenue was 731 million yuan, a year-on-year increase of 1.54%. The net profit attributable to shareholders of the listed company was 131 million yuan, a year-on-year decrease of 3.54%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves

    Zhitong·
    SZ
    002349
    -1.36%
    Zhitong·
    SZ
    002349
    -1.36%

    JINGHUA PHARM: Ritonavir has received approval for the listing application of chemical raw materials

    JINGHUA PHARM announced that its subsidiary Nantong Company has obtained approval from the National Medical Products Administration for the marketing application of Ritonavir chemical raw materials. This antiviral drug is primarily used for the treatment of AIDS and has also been widely used during the COVID-19 pandemic. This approval means that the raw materials meet national review standards and can be produced and sold in the domestic market in the future, enhancing the company's competitiveness in the field of chemical raw materials

    Zhitong·
    SZ
    002349
    -1.36%
    Zhitong·
    SZ
    002349
    -1.36%
    © 2025 Longbridge｜Disclaimer